EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyse

Abstract 4282: Morning versus Nighttime Antihypertensive Dosing and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials

vinicius parreira, Lidia Cheidde, Amanda Deolindo Silva, Mateus Megiolaro, Bruna Giffoni, Karlos Daniell Araujo Dos Santos, Ricardo Suruagy-Motta, Khaled M. Harmouch

Circulation · 02.11.2026 · 154 (Suppl_1)

DOI: 10.1161/circ.154.suppl_1.4282 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Circulation, erschienen am 02.11.2026. Verfasst von vinicius parreira und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The optimal timing of antihypertensive therapy remains uncertain despite recent large randomized trials. We conducted an updated systematic review and meta-analysis to compare morning versus nighttime dosing on cardiovascular outcomes.

Methods

We systematically searched PubMed, Embase, and Web of Science for randomized controlled trials enrolling patients with hypertension assigned to morning or nighttime dosing. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using random-effects models, and heterogeneity was assessed using the I 2 statistic. Sensitivity analyses were performed using a leave-one-out approach.

Results

Five randomized controlled trials including 42,075 participants were analyzed. No significant differences were observed between morning and nighttime dosing for all-cause mortality (RR 0.99; 95% CI 0.91-1.08; I 2 =0%), myocardial infarction (RR 1.14; 95% CI 0.98-1.33; I 2 =0%), major adverse cardiovascular events (RR 1.04; 95% CI 0.92-1.19; I 2 =0%), or stroke (RR 0.95; 95% CI 0.75-1.20; I 2 =49.9%). Sensitivity analyses confirmed the robustness of these findings, with consistent results across leave-one-out evaluations.

Conclusions

Morning and nighttime antihypertensive dosing strategies were associated with similar cardiovascular outcomes. Dosing time was not associated with differences in major cardiovascular events and does not appear to be a key determinant of cardiovascular risk reduction.

Zitieren

APA

parreira, V., Cheidde, L., Silva, A. D., Megiolaro, M., Giffoni, B., Santos, K. D. A. D., Suruagy-Motta, R., & Harmouch, K. M. (2026). Abstract 4282: Morning versus Nighttime Antihypertensive Dosing and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation, 154(Suppl_1). https://doi.org/10.1161/circ.154.suppl_1.4282

Vancouver

parreira V, Cheidde L, Silva AD, Megiolaro M, Giffoni B, Santos KDAD, et al. Abstract 4282: Morning versus Nighttime Antihypertensive Dosing and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2026;154(Suppl_1). doi:10.1161/circ.154.suppl_1.4282

BibTeX
@article{parreira2026,
  author = {parreira, vinicius and Cheidde, Lidia and Silva, Amanda Deolindo and Megiolaro, Mateus and Giffoni, Bruna and Santos, Karlos Daniell Araujo Dos and Suruagy-Motta, Ricardo and Harmouch, Khaled M.},
  title = {Abstract 4282: Morning versus Nighttime Antihypertensive Dosing and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomized Trials},
  journal = {Circulation},
  year = {2026},
  volume = {154},
  number = {Suppl_1},
  doi = {10.1161/circ.154.suppl_1.4282}
}
Kostenlos starten →